Cargando…

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer

BACKGROUND: CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated. METHODS: Within a prospective single-centre study serial blood samples were collected from patients with confirmed advanced PC. Pre-treatment valu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boeck, S, Wittwer, C, Heinemann, V, Haas, M, Kern, C, Stieber, P, Nagel, D, Holdenrieder, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668481/ https://www.ncbi.nlm.nih.gov/pubmed/23579210 http://dx.doi.org/10.1038/bjc.2013.158

Ejemplares similares

Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer
por: Uenishi, T, et al.
Publicado: (2003)

Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples
por: Thomas, D S, et al.
Publicado: (2015)

Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)

Clinical Usefulness of CYFRA Assay in Diagnosing Lung Cancer: Measurement of Serum Cytokeratin Fragment
por: Sugama, Yasuo, et al.
Publicado: (1994)

Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
por: Giovanella, L., et al.
Publicado: (2017)

Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
por: Xu, Youtao, et al.
Publicado: (2015)

Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
por: Takada, M., et al.
Publicado: (1995)

Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma
por: Xue, A, et al.
Publicado: (2012)

Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer
por: Nakata, B, et al.
Publicado: (2004)

Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer
por: PANG, LI, et al.
Publicado: (2013)

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer
por: Kuefer, R, et al.
Publicado: (2005)

Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis
por: Xue, A, et al.
Publicado: (2010)

Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer
por: Wood, S L, et al.
Publicado: (2010)

New Immunosensing-Fluorescence Detection of Tumor Marker Cytokeratin-19 Fragment (CYFRA 21-1) Via Carbon Quantum Dots/Zinc Oxide Nanocomposite
por: Alarfaj, Nawal Ahmed, et al.
Publicado: (2020)

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
por: Tonack, S, et al.
Publicado: (2013)

Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT–PCR detection of cytokeratin 19 mRNA
por: Tao, L, et al.
Publicado: (2006)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2009)

Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells
por: Kaistha, B P, et al.
Publicado: (2014)

Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma
por: Rückert, F, et al.
Publicado: (2008)

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
por: Kahlert, C, et al.
Publicado: (2009)

Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients
por: Szkandera, J, et al.
Publicado: (2014)

Evaluation of serum cyfra21 in patients with pleural effusion
por: Azimi, Q, et al.
Publicado: (2012)

Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival
por: Li, Z, et al.
Publicado: (2011)

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
por: Mitsunaga, S, et al.
Publicado: (2013)

Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis
por: Cho, W C S, et al.
Publicado: (2010)

Endostatin expression in pancreatic tissue is modulated by elastase
por: Brammer, R D, et al.
Publicado: (2005)

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
por: Trillsch, Fabian, et al.
Publicado: (2016)

Clinical significance of serum CYFRA 21-1 in gastric cancer.
por: Nakata, B., et al.
Publicado: (1996)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

A novel fragment derived from the β chain of human fibrinogen, β43–63, is a potent inhibitor of activated endothelial cells in vitro and in vivo
por: Krajewska, E, et al.
Publicado: (2010)

miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions
por: Grignol, V, et al.
Publicado: (2011)

Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
por: Smith, R A, et al.
Publicado: (2011)

Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas
por: Handra-Luca, A, et al.
Publicado: (2011)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion
por: Hooper, S, et al.
Publicado: (2010)

Poly(A) RT–PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer
por: Oliveira-Cunha, M, et al.
Publicado: (2011)

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
por: Cheng, W-F, et al.
Publicado: (2009)

Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer
por: Yang, Q, et al.
Publicado: (2014)

Serum biomarker panels for the diagnosis of gastric adenocarcinoma
por: Ahn, H S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qo9ld8vhs9l9dau2k7ljv2i1h0